Waystar Considers Sale Amidst Market Challenges

Waystar, a prominent healthcare software company, is reportedly considering a range of strategic options, including a potential sale. This comes two years after its initial public offering on the New York Stock Exchange. According to sources familiar with the situation, the firm has engaged investment bank Evercore to assist with the process, although discussions are still in the preliminary stages.

The company, headquartered in both Lehi, Utah, and Louisville, Kentucky, specializes in software that automates and manages administrative tasks for hospitals and medical professionals. This positioning aims to capitalize on higher valuations typically granted to tech firms compared to healthcare service providers reliant on human labor.

Investment Challenges and Market Valuation

Waystar's market value has declined to approximately $4.8 billion, following a 24% drop in its share price this year. This downturn is part of a broader selloff in the software sector. Despite the initial enthusiasm that saw its share price rise from $20 to a peak of $45 in 2025, investor confidence has waned. Analysts from Morgan Stanley have noted concerns about the potential impact of advancements in artificial intelligence on software companies as a contributing factor.

Waystar was established in 2017 through the merger of Zirmed and Navicure, two healthcare revenue management companies. The firm's major shareholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, with EQT holding a 13% stake, CPPIB 10%, and BlackRock Institutional Trust Company 8%, according to LSEG data.

Potential Outcomes and Industry Implications

While the exploration of a sale could potentially return Waystar to private ownership, sources caution that plans are not finalized and could be subject to change. A sale, if it proceeds, might indicate a renewed investor interest in software enterprises, providing a litmus test for the sector’s current appeal.

Both Waystar and its advisors have declined to comment on the ongoing discussions. Similarly, EQT, CPPIB, and BlackRock have either declined or not responded to requests for comment.

The situation reflects broader trends in the healthcare and technology sectors, where companies are actively reassessing their market strategies amidst economic fluctuations and technological advancements. As the landscape evolves, Waystar's decision could set a precedent for similar firms navigating the complexities of public and private market dynamics.